$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

$auph Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021021464 Filed on November 03, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$23.40M	$14.67M	$29.00K
YoY Change	-53.22%	50475.86%	-87.39%
Cost Of Revenue	$481.0K	$254.0K	$0.00
YoY Change
Gross Profit	$22.92M	$14.41M	$29.00K
YoY Change		49600.0%
Gross Profit Margin	97.94%	98.27%	100.0%
Selling, General & Admin	$44.24M	$44.13M	$30.70M
YoY Change	-53.91%	43.73%	406.63%
% of Gross Profit	193.0%	306.17%	105868.97%
Research & Development	$11.15M	$20.07M	$12.24M
YoY Change	-15.35%	63.9%	-31.18%
% of Gross Profit	48.64%	139.22%	42217.24%
Depreciation & Amortization	$688.0K	$200.0K	$0.00
YoY Change	67.8%		-100.0%
% of Gross Profit	3.0%	1.39%	0.0%
Operating Expenses	$56.11M	$65.02M	$42.34M
YoY Change	-3.4%	53.55%	74.27%
Operating Profit	-$32.71M	-$50.35M	-$42.32M
YoY Change	306.17%	19.0%	75.81%
Interest Expense	$109.0K	$106.0K	$170.0K
YoY Change	-92.81%	-37.65%	-96.69%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$32.60M	-$50.25M	-$42.15M
YoY Change	-68.28%	19.22%	121.7%
Income Tax	$726.0K	$8.000K	-$15.00K
% Of Pretax Income
Net Earnings	-$33.32M	-$50.26M	-$42.13M
YoY Change	312.71%	19.29%	79.63%
Net Earnings / Revenue	-142.38%	-342.64%	-145275.86%
Basic Earnings Per Share	-$0.25	-$0.39	-$0.34
Diluted Earnings Per Share	-$0.25	-$0.39	-$0.34
COMMON SHARES
Basic Shares Outstanding	129.7M shares	128.4M shares	122.4M shares
Diluted Shares Outstanding		128.4M shares	122.4M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$466.1M	$286.4M	$392.0M
YoY Change	17.01%	-26.94%	191.47%
Cash & Equivalents	$231.6M	$57.59M	$248.8M
Short-Term Investments	$234.2M	$228.8M	$143.3M
Other Short-Term Assets	$796.0K	$728.0K	$11.71M
YoY Change	-21.81%	-93.79%	225.39%
Inventory	$19.33M	$19.29M	$471.0K
Prepaid Expenses	$12.51M	$13.71M
Receivables	$15.41M	$9.814M	$1.129M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$513.3M	$329.2M	$405.3M
YoY Change	22.39%	-18.78%	192.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.418M	$4.551M	$9.704M
YoY Change	-7.69%	-53.1%	2326.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$28.78M
YoY Change	-100.0%	-100.0%
Other Assets	$11.84M	$11.84M	$209.0K
YoY Change	4692.71%	5564.11%	4.5%
Total Long-Term Assets	$30.04M	$30.85M	$47.72M
YoY Change	-32.08%	-35.36%	291.14%
TOTAL ASSETS
Total Short-Term Assets	$513.3M	$329.2M	$405.3M
Total Long-Term Assets	$30.04M	$30.85M	$47.72M
Total Assets	$543.4M	$360.1M	$453.1M
YoY Change	17.19%	-20.53%	200.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.879M	$3.263M	$20.19M
YoY Change	-84.36%	-83.84%	51.8%
Accrued Expenses	$32.13M	$27.82M
YoY Change	3977.03%
Deferred Revenue	$190.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$40.65M	$37.54M	$24.31M
YoY Change	27.03%	54.43%	80.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$16.00M	$16.60M	$19.32M
YoY Change	-1.84%	-14.06%	45.23%
Total Long-Term Liabilities	$16.00M	$16.60M	$19.32M
YoY Change	-1.84%	-14.06%	42.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.65M	$37.54M	$24.31M
Total Long-Term Liabilities	$16.00M	$16.60M	$19.32M
Total Liabilities	$64.28M	$61.89M	$43.62M
YoY Change	14.96%	41.88%	60.97%
SHAREHOLDERS EQUITY
Retained Earnings	-$756.1M	-$722.8M
YoY Change	31.46%
Common Stock	$59.01M	$54.61M
YoY Change	49.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$479.1M	$298.2M	$409.4M
YoY Change
Total Liabilities & Shareholders Equity	$543.4M	$360.1M	$453.1M
YoY Change	17.19%	-20.53%	200.44%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$33.32M	-$50.26M	-$42.13M
YoY Change	312.71%	19.29%	79.63%
Depreciation, Depletion And Amortization	$688.0K	$200.0K	$0.00
YoY Change	67.8%		-100.0%
Cash From Operating Activities	-$25.92M	-$40.25M	-$28.42M
YoY Change	-909.05%	41.65%	141.22%
INVESTING ACTIVITIES
Capital Expenditures	-$35.00K	-$63.00K	-$4.654M
YoY Change	-98.4%	-98.65%	-15613.33%
Acquisitions
YoY Change
Other Investing Activities	-$5.452M	-$32.74M	-$139.8M
YoY Change	-125.56%	-76.59%
Cash From Investing Activities	-$5.487M	-$32.81M	-$144.5M
YoY Change	-128.66%	-77.3%	481556.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	205.7M	9.082M	189.3M
YoY Change	16463.77%	-95.2%	1174.46%
NET CHANGE
Cash From Operating Activities	-25.92M	-40.25M	-28.42M
Cash From Investing Activities	-5.487M	-32.81M	-144.5M
Cash From Financing Activities	205.7M	9.082M	189.3M
Net Change In Cash	174.3M	-63.97M	16.34M
YoY Change	638.86%	-491.42%	437.63%
FREE CASH FLOW
Cash From Operating Activities	-$25.92M	-$40.25M	-$28.42M
Capital Expenditures	-$35.00K	-$63.00K	-$4.654M
Free Cash Flow	-$25.89M	-$40.19M	-$23.76M
YoY Change	-580.55%	69.12%	101.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001600620
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36421
	dei	Entity Registrant Name EntityRegistrantName	Aurinia Pharmaceuticals Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Z4
	dei	Entity Address Address Line1 EntityAddressAddressLine1	#1203-4464 Markham Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Victoria
	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V8Z 7X8
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-4129078
	dei	City Area Code CityAreaCode	(250)
	dei	Local Phone Number LocalPhoneNumber	708-4272
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	129670345	shares
	dei	Security12b Title Security12bTitle	Common shares, no par value
	dei	Trading Symbol TradingSymbol	AUPH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57587000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272350000	USD
CY2021Q3	us-gaap	Debt Securities Current DebtSecuritiesCurrent	228813000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2021Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9814000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	0	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	19293000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13927000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13712000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7171000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	329219000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	419427000	USD
CY2021Q3	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	24380000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11838000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	247000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4551000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8926000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5532000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2021Q3	us-gaap	Assets Assets	360066000	USD
CY2020Q4	us-gaap	Assets Assets	463661000	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	29970000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2000000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	6000000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6456000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6412000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1111000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	37537000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31997000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16562000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16295000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7795000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	61894000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	55911000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	129570000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129570000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126725000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126725000	shares
CY2021Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	967159000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	944328000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	54607000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	39383000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-794000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-805000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-722800000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575156000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	298172000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	360066000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463661000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14667000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22201000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	88000	USD
CY2021Q3	us-gaap	Cost Of Revenue CostOfRevenue	254000	USD
CY2020Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Cost Of Revenue CostOfRevenue	610000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44128000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30702000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	127196000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57204000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20066000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12243000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39990000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37154000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	517000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	316000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1576000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	902000	USD
CY2021Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-55000	USD
CY2020Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	917000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-859000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1066000	USD
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	65020000	USD
CY2020Q3	us-gaap	Costs And Expenses CostsAndExpenses	42344000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	170231000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	96326000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-50353000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-42315000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-148030000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-96238000	USD
CY2021Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	106000	USD
CY2020Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	170000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	420000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1381000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-50247000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42145000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-147610000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94857000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-251000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-50255000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-42130000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-147644000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-94606000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	11000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-50257000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42130000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-147633000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-94606000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128443000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128443000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	122357000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	122357000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128084000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128084000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115738000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115738000	shares
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	332257000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9074000	USD
CY2021Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	6000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7092000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-50255000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-50255000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	298172000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	257698000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1525000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	12268000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4611000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-42130000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-42130000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	409436000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	407750000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	15352000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	37000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	22666000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	11000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-147644000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	298172000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	298600000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5400000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	12268000	USD
	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	1000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12309000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-94606000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	409436000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-147644000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-94606000	USD
	us-gaap	Depreciation Depreciation	497000	USD
	us-gaap	Depreciation Depreciation	59000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1576000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	902000	USD
	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	10000000	USD
	auph	Acquired Upfront License Payment AcquiredUpfrontLicensePayment	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	22666000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12309000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1005000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-736000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	9815000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5366000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	471000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	6541000	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3725000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-247000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	43000	USD
	auph	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	5576000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1149000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9012000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	499000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	8298000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-131770000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-73062000	USD
CY2021Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9800000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	342831000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	202951000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	263752000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	30779000	USD
	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	11838000	USD
	us-gaap	Payments To Acquire Lease Receivables PaymentsToAcquireLeaseReceivables	0	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	6000000	USD
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	0	USD
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	262000	USD
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	4095000	USD
	us-gaap	Payments For Software PaymentsForSoftware	1198000	USD
	us-gaap	Payments For Software PaymentsForSoftware	982000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6000	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	83000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-98383000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-177332000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15353000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5400000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	37000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	187732000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15390000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	193133000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-214763000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57261000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	272350000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	306019000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57587000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	248758000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	671000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	891000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	236000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	62000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	195000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	68000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	419000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5804000	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of December 31, 2020 was derived from audited annual financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for the full year or any other future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one operating segment in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from license, contract and product revenues. The Company's chief executive officer makes decisions for the Company and its subsidiaries as a whole. Accordingly, the Company operates and makes decisions as one reporting unit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements are presented in U.S. dollars which is the Company's functional currency therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statement of operations. All assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Revenues and expenses are remeasured at the average exchange rate during the period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the condensed consolidated statements of operations.</span></div>We are devoting the majority of our operational efforts and financial resources towards the commercialization and post approval commitments of our approved drug, LUPKYNIS. We are also expending efforts towards our newly acquired assets AUR200 and AUR300. Taking into consideration the Company's cash and cash equivalents and investments of $286.4 million as of September 30, 2021, the Company believes that it has sufficient resources to fund its operations at least one year beyond the date that the unaudited condensed consolidated financial statements are issued.
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingUnit
CY2021Q3	auph	Cash Cash Equivalents And Debt Securities Current CashCashEquivalentsAndDebtSecuritiesCurrent	286400000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities in our condensed consolidated financial statements. We believe the most complex judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to our condensed consolidated financial statements. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. We evaluate our estimates, judgments and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions and such differences may be material.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant areas involving estimates, judgments and assumptions used in the preparation of our condensed consolidated financial statements are as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue recognition;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inventory;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Royalty obligation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent accruals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial expenditures;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible assets; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leases; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income taxes.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, investments and accounts receivable. The Company attempts to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company may at times maintain cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the United States dollar and foreign currencies, primarily with the Canadian dollar, will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses are also denominated in U.S. dollars, which limits the risk of material foreign exchange fluctuations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has three main customers for U.S. commercial sales of LUPKYNIS and one customer for sales of voclosporin in the European Union, Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. Revenues from two customers accounted for approximately 59% and 40% of the Company's total revenues for the three and nine months ended September 30, 2021. The Company monitors economic conditions, the </span></div>creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. An allowance against accounts receivable is established, if needed, using an expected credit loss model. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and the Company could potentially incur credit losses.
CY2020Q4	us-gaap	Interest Receivable InterestReceivable	500000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-2000	USD
CY2021Q3	us-gaap	Debt Securities Current DebtSecuritiesCurrent	228800000	USD
CY2021Q3	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	0	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	126000000	USD
CY2020Q4	us-gaap	Debt Securities Noncurrent DebtSecuritiesNoncurrent	24400000	USD
CY2021Q3	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	21500000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	207300000	USD
CY2020Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	150400000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0	USD
CY2021Q3	us-gaap	Debt Securities Current DebtSecuritiesCurrent	228813000	USD
CY2020Q4	us-gaap	Debt Securities Current DebtSecuritiesCurrent	125979000	USD
CY2021Q3	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	228813000	USD
CY2020Q4	auph	Debt Securities Current And Noncurrent DebtSecuritiesCurrentAndNoncurrent	150359000	USD
CY2021Q3	us-gaap	Interest Receivable InterestReceivable	100000	USD
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	11000	USD
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2217000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2021Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12074000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13927000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5002000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	19293000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	13927000	USD
CY2021Q3	us-gaap	Prepaid Advertising PrepaidAdvertising	5871000	USD
CY2020Q4	us-gaap	Prepaid Advertising PrepaidAdvertising	3701000	USD
CY2021Q3	us-gaap	Prepaid Insurance PrepaidInsurance	2524000	USD
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2054000	USD
CY2021Q3	us-gaap	Other Assets Current OtherAssetsCurrent	728000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1018000	USD
CY2021Q3	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	4589000	USD
CY2020Q4	auph	Prepaid Rent And Prepaid Continuing Studies PrepaidRentAndPrepaidContinuingStudies	398000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13712000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7171000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	19469000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10543000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8926000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18452000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9120000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	9332000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1600000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5224000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4965000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	673000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	179000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4551000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4786000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	200000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	0	USD
	us-gaap	Depreciation Depreciation	500000	USD
	us-gaap	Depreciation Depreciation	100000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5532000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5489000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1111000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	788000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7795000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7619000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	8906000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8407000	USD
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	261000	USD
CY2020Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	196000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	783000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	456000	USD
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	7000	USD
CY2020Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	74000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	21000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	215000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	44000	USD
CY2020Q3	us-gaap	Variable Lease Cost VariableLeaseCost	1000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	124000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	3000	USD
CY2021Q3	us-gaap	Lease Cost LeaseCost	312000	USD
CY2020Q3	us-gaap	Lease Cost LeaseCost	271000	USD
	us-gaap	Lease Cost LeaseCost	928000	USD
	us-gaap	Lease Cost LeaseCost	674000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y8M4D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0520
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	281000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1143000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1061000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1085000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1109000	USD
CY2021Q3	auph	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	6773000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11452000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2546000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	8906000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	11800000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	84000000	USD
CY2021Q3	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	84000000	USD
CY2021Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3263000	USD
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2635000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8322000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6616000	USD
CY2021Q3	auph	Accrued Research Current AccruedResearchCurrent	3865000	USD
CY2020Q4	auph	Accrued Research Current AccruedResearchCurrent	4185000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	14520000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11361000	USD
CY2021Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	29970000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24797000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16600000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16300000	USD
CY2021Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	228813000	USD
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	286400000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	150359000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	422709000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-50255000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-42130000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-147644000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-94606000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128443000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128443000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	122357000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	122357000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	128084000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	128084000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115738000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	115738000	shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.15
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14907000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13133000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	129600000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129600000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126700000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126700000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.66
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.43
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-251000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0038
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0070
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.089
	auph	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0.000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.64
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.05
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7092000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4611000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22666000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12309000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	16900000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M6D
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15000	USD

Files In Submission

Name	View Source	Status
0001628280-21-021464-index-headers.html	Edgar Link	pending
0001628280-21-021464-index.html	Edgar Link	pending
0001628280-21-021464.txt	Edgar Link	pending
0001628280-21-021464-xbrl.zip	Edgar Link	pending
auph-20210930.htm	Edgar Link	pending
auph-20210930.xsd	Edgar Link	pending
auph-20210930_cal.xml	Edgar Link	unprocessable
auph-20210930_def.xml	Edgar Link	unprocessable
auph-20210930_htm.xml	Edgar Link	completed
auph-20210930_lab.xml	Edgar Link	unprocessable
auph-20210930_pre.xml	Edgar Link	unprocessable
auph-2021q3exx311.htm	Edgar Link	pending
auph-2021q3exx312.htm	Edgar Link	pending
auph-2021q3exx321.htm	Edgar Link	pending
auph-2021q3exx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph

2021 Q4 Form 10-Q Financial Statement

#000162828021021464 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH Aurinia Pharmaceuticals Inc. Stock $auph

2021 Q4 Form 10-Q Financial Statement

#000162828021021464 Filed on November 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AUPH
Aurinia Pharmaceuticals Inc. Stock $auph